Nat Neurosci. 2007 Jan; 10 (1): 93-9 . Epub 2006 Dec 3.
Onye isi ala SJ1, Bolanos CA, Theobald DE, DeCarolis NA, Renthal W, Kumar A, Winstanley CA, Renthal NE, Wiley MD, Onwe DW, Russell DS, Enweghị RL, Eisch AJ, Nestler EJ.
nkịtị
Nlekọta morphine na-adịghị ala ala (site na pellet subcutaneous) na-ebelata nha nke neurons dopamine na mpaghara ventral tegmental (VTA), mpaghara ụgwọ ọrụ dị na ụbụrụ, mana amabeghị ihe ndabere mkpụrụ ndụ na nsonaazụ ọrụ nke nsonaazụ a. N'ime ọmụmụ ihe a, anyị na-eji mbufe mkpụrụ ndụ ihe gbasara nje na oke na sKedu ka mbelata nke morphine na-adịghị ala ala nke insulin receptor substrate 2 (IRS2) -thymoma viral proto-oncogene (Akt) ụzọ akara na VTA na-eme ka mbelata nke mkpụrụ ndụ dopamine nke a hụrụ mgbe mkpughe morphine na nke a na-ebelata ụgwọ ọrụ morphine, dị ka atụpụtara site na mmasị ebe nwere oyiri. Anyị na-egosikwa na mbelata nke neurons VTA dopamine na-adịgide ruo izu 2 ka mwepu morphine gachara, nke kwekọrọ na nnabata na nsonaazụ ụgwọ ọrụ morphine kpatara site na mkpughe morphine na-adịghị ala ala gara aga. Nchọpụta ndị a na-emetụta kpọmkwem ụzọ akara IRS2-Akt dị ka onye na-achịkwa morphology cell dopamine na ụgwọ ọrụ opiate.
;